Get started with the ApellisAssist® ECP Portal

Indication: SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy, or GA, secondary to age-related macular degeneration, or AMD.

Select Safety Information: SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation.

Additional Important Safety Information for SYFOVRE will be covered at the end of this video.

Hello, and welcome to getting started with the ApellisAssist Eyecare Professional portal.

Once your office decides SYFOVRE is the right treatment for your patient, the ApellisAssist program can help patients gain access to the product.

To help introduce the ECP portal, meet our guide, Eileen, an eyecare practice manager.

In this video, we’ll follow Eileen as she gets her practice started using the ECP portal.

You’ll learn how to register your practice, enroll a patient in the ApellisAssist program through the portal, and take a tour through available portal services and resources.

Note that if you have already registered your practice with the ECP portal and have an account, feel free to move ahead in this video to Chapter 2: Enroll a patient.

If you have not yet registered, let’s start there.

Chapter 1: Register your practice.

Before Eileen dives in, please note that the portal contains protected health information, and portal users should have appropriate authorizations or permissions to access such information.

There is also an important point to consider when registering, especially if your practice has multiple offices or locations.

You can proceed using either of two options:

In the first option, you would create one parent account for your entire practice, then add each office as a location under that main account. This method allows the account administrator and users to view and manage all of your practice’s patients enrolled in the portal, across all your offices, from a single parent account.

In the second option, each office or location in your practice would create its own portal account with separate organization information. This method allows multiple accounts for your practice, but the administrators and users of the separate accounts can only view and manage the enrolled patients aligned with their specific office or location.

Whether you create one portal account for your practice or several, the registration process remains the same.

On the next several screens, we’ll view Eileen’s monitor as she goes through the registration process.

And that’s it. We’ve seen Eileen register her practice, set up her account and password, and log into the portal. Thanks, Eileen.

Chapter 2: Enroll a patient

Enrolling your patients in the ApellisAssist program provides them with a support system that may assist with insurance support, educational resources, and financial assistance for eligible patients.

Now that Eileen has registered and logged in, we’ll view her monitor and follow along again as she enrolls one of her practice’s patients using the ECP portal.

And with that, Eileen has registered her practice’s first patient in the ApellisAssist program through the ECP portal.

For each new patient your practice enrolls through the portal, you’ll proceed through the same process.

Thanks again, Eileen.

Chapter 3: Explore portal resources

Once enrolled, the ApellisAssist program offers patients a wide range of support services along their treatment journey. And for your practice, the ApellisAssist ECP portal provides a single, secure digital interface.

Now that Eileen has enrolled a patient, let’s view her monitor again for a quick tour of the additional services and resources available to you via the ECP portal.

Well, we’ve come to the end of Eileen’s tour through the ECP portal introductory video! Thanks again, Eileen, and thank you for viewing.

Hopefully it’s been helpful in getting you and your patients off to a great start on the access and support journey with the ApellisAssist program.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

• SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

• Endophthalmitis and Retinal Detachments
• Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
• Retinal Vasculitis and/or Retinal Vascular Occlusion
• Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
• Neovascular AMD
• In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
• Intraocular Inflammation
• In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
• Increased Intraocular Pressure
• Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

• Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see full Prescribing Information for more information.